CG Oncology, Inc. CGON
65.33 USD +3.37 (+5.43%)
Nov 3, 2026, 3:16 PM EST
62.35 Day range 65.79
35.80 52-week range 80.97
- YTD
- +57.34%
- 1 year
- +55.91%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 91.08 +39.4% upside
Now 65.33
- Target (low)
- 79.00
- Target (mean)
- 91.08
- Target (high)
- 108.00
Ratings (0m) 15 14 buy · 1 hold · 0 sell
- Strong buy4
- Buy10
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 15
- 2 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.80966 | -0.96 – -0.66 | -0.57 | -42.0% | 534.48K | -67.9% | 12 |
| Next quarter | -0.83815 | -1.03 – -0.67 | -0.51 | -64.3% | 531.18K | -77.1% | 12 |
| Current year | -3.23 | -3.60 – -2.79 | -2.08 | -55.3% | 4.45M | +10.3% | 12 |
| Next year | -3.02 | -3.63 – -2.15 | -3.23 | +6.5% | 83.51M | +1774.8% | 12 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 7, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 7, 2026 | Truist Securities | Maintained | Buy | Buy |
| May 19, 2026 | Wolfe Research | Initiated | — | Peer Perform |
| May 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 14, 2026 | Truist Securities | Reiterated | Buy | Buy |
| May 11, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| May 11, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 11, 2026 | Truist Securities | Reiterated | Buy | Buy |
| May 11, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 27, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 17, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Apr 7, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 27, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 10, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jan 21, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jan 16, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Jan 12, 2026 | Truist Securities | Maintained | Buy | Buy |
| Dec 11, 2025 | Wedbush | Initiated | — | Outperform |
| Nov 24, 2025 | Truist Securities | Initiated | — | Buy |
| Nov 17, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 8, 2025 | Guggenheim | Initiated | — | Buy |
| Sep 26, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 17, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 15, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 8, 2025 | Jones Trading | Initiated | — | Buy |
| Sep 8, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 8, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 5, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 19, 2025 | Piper Sandler | Initiated | — | Overweight |